- Home
- AIRI vs NRXS Comparison
AIRI vs NRXS Comparison
Compare AIRI & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- NRXS
- Stock Information
- Founded
- AIRI 1979
- NRXS 2011
- Country
- AIRI United States
- NRXS United States
- Employees
- AIRI N/A
- NRXS N/A
- Industry
- AIRI Military/Government/Technical
- NRXS
- Sector
- AIRI Industrials
- NRXS
- Exchange
- AIRI Nasdaq
- NRXS Nasdaq
- Market Cap
- AIRI 13.4M
- NRXS 12.5M
- IPO Year
- AIRI N/A
- NRXS 2023
- Fundamental
- Price
- AIRI $3.24
- NRXS $2.42
- Analyst Decision
- AIRI
- NRXS
- Analyst Count
- AIRI 0
- NRXS 0
- Target Price
- AIRI N/A
- NRXS N/A
- AVG Volume (30 Days)
- AIRI 12.9K
- NRXS 36.9K
- Earning Date
- AIRI 04-15-2025
- NRXS 05-21-2025
- Dividend Yield
- AIRI N/A
- NRXS N/A
- EPS Growth
- AIRI N/A
- NRXS N/A
- EPS
- AIRI N/A
- NRXS N/A
- Revenue
- AIRI $55,108,000.00
- NRXS $2,685,925.00
- Revenue This Year
- AIRI $1.80
- NRXS $138,883.78
- Revenue Next Year
- AIRI N/A
- NRXS $118.59
- P/E Ratio
- AIRI N/A
- NRXS N/A
- Revenue Growth
- AIRI 6.97
- NRXS 9.18
- 52 Week Low
- AIRI $3.00
- NRXS $1.33
- 52 Week High
- AIRI $9.44
- NRXS $3.78
- Technical
- Relative Strength Index (RSI)
- AIRI 41.93
- NRXS 65.87
- Support Level
- AIRI $3.02
- NRXS $1.33
- Resistance Level
- AIRI $3.36
- NRXS $2.09
- Average True Range (ATR)
- AIRI 0.18
- NRXS 0.36
- MACD
- AIRI 0.01
- NRXS 0.06
- Stochastic Oscillator
- AIRI 47.06
- NRXS 90.95
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).